Novartis’ psoriasis trial data for Cosentyx outshines Johnson and Johnson competitor

Novartis has recently released trial data showing that Cosentyx was shown to be significantly more effective in treating patients with psoriasis when compared to the Johnson & Johnson’s rival biologic Stelara. According to the published results from the head-to-head CLARITY study, 66.5% of patients treated with Cosentyx achieved the primary endpoint PASI 90 (a 90%

Continue Reading

Allergan and Novartis to collaborate on new NASH therapy trials

Allergan is set to expand its research and development programme on non-alcoholic steatohepatitis (NASH) through a partnership with Novartis that will test a new combination therapy approach for the condition. The pharmaceutical firms have signed a clinical trial agreement under which Novartis will carry out a Phase IIb study testing Allergan’s cenicriviroc (CVC), a once-daily,

Continue Reading

Positive Clinical Trial Results for Novartis’ Signifor

Novartis have released data from a phase III clinical trial suggesting that their somatostatin analogue, Signifor, could be effective for the growth hormone disorder, acromegaly. The recent clinical trial assessed a once-monthly intramuscular formulation, named Signifor LAR, in patients with acromegaly where standard therapies had been ineffective.  Signifor has already been approved by regulators in

Continue Reading

Novartis’ Bimagrumab Awarded Breakthrough Status

US regulators have granted Novartis’ experimental muscle wasting drug, bimagrumab, ‘breakthrough’ status, potentially granting it fast-track to being approved. The US Food and Drug Administration (FDA) has decided to grant BYM338 (bimagrumab) a potential breakthrough because, if it is approved, it could become the first treatment for patients with sporadic inclusion body myositis, a rare

Continue Reading

Jetrea Launched by Novartis in the UK

Novartis’ Alcon unit has released Jetrea in the UK,  its first market.  The launch is under a month after European Commission approved Jetrea for the treatment of vitreomacular traction. Vitreomacular traction (VMT) is an age-related progressive, sight-threatening condition.  Jetrea was approved for VMT, including when associated with macular hole of diameter less than or equal

Continue Reading

Novartis Generates 100 New Jobs in Ireland

Novartis have announced that they will be expanding their presence in Ireland, setting up a business services centre in Dublin. The move, which will create 100 additional jobs, will combine the digital marketing, sales force training and medical communications services for the organisation.  The centre is being established at Novartis’ existing campus in Beech Hill,

Continue Reading

NICE Provides Final Draft Guidance for Lucentis

UK drugs watchdog, NICE, have endorsed the use of Lucentis on the NHS to treat visual impairment caused by diabetic macular oedema after Novartis submitted a revised patient access scheme (PAS) and new drug data. The National Institute for Health and Clinical Excellence published the final draft guidance after a rapid review of the original

Continue Reading

Xolair Endorsement Retracted by NICE

The National Institute for Health and Clinical Excellence (NICE) have released draft guidance withdrawing their recommendation of Novartis’ Xolair for severe persistent allergic asthma. In 2007, NICE circulated guidelines supporting the use of Xolair (omalizumab) on the National Health Service (NHS) for adults whose asthma is poorly controlled.  Then in 2011 they reject the treatment’s

Continue Reading

Novartis’ Afinitor Approved for Breast Cancer by FDA

Novartis announced on Friday that they have received approval from US regulators for Afinitor as a treatment for advanced breast cancer. The US Food and Drug Administration (FDA) have given the thumbs up to Afinitor (everolimus) for use with Pfizer’s Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.  The

Continue Reading

Novartis’ GIST Drug, Glivec, Receives European Commission Approval

Novartis announced earlier today that the European Commission has approved an update to their Glivec (imatinib) label to include 36 months of treatment after surgery, for adults with KIT (CD117)-positive gastrointestinal stromal tumours (GIST) who met the inclusion conditions of the pivotal study. The prolonged treatment has been demonstrated to increase recurrence-free survival and the

Continue Reading